tavokinogene telseplasmid + pembrolizumab + nab-paclitaxel

A combination regimen consisting of **tavokinogene telseplasmid** (a gene therapy or immunomodulatory plasmid), **pembrolizumab** (a monoclonal antibody targeting PD-1 checkpoint to boost anti-tumor immunity), and **nab-paclitaxel** (a nano-albumin bound formulation of paclitaxel with cytotoxic anti-microtubule activity). **Pembrolizumab** works by blocking PD-1, restoring T-cell mediated tumor cytotoxicity[1][4]. **Nab-paclitaxel** disrupts microtubule dynamics in tumor cells, leading to apoptosis, and its albumin-binding allows improved efficacy and tolerability over standard paclitaxel[1][5]. While tavokinogene telseplasmid is generally used to stimulate anti-tumor immune responses (for example, through cytokine gene expression), the precise mechanism and indication in the context of this triple regimen presume immunogenic enhancement alongside immune checkpoint inhibition and chemotherapy. This combination is under investigation for solid tumors such as locally advanced or metastatic triple-negative breast cancer and head and neck squamous cell carcinoma, aiming to synergize cytotoxic and immunotherapeutic effects to maximize anti-tumor efficacy[5][7].

Brand names

Keytruda (pembrolizumab)Abraxane (nab-paclitaxel)

Other names

OBI-822 (tavokinogene telseplasmid, if used as synonym)nano-albumin-bound paclitaxel (nab-paclitaxel)PD-1 inhibitor (pembrolizumab)